In the Canadian CanCOLD cohort, 48 of 685 participants (7.0 %) without airflow obstruction were newly classified as having COPD under the minor-criteria path, while 105 of 656 participants (16.0 % ...

Compared with patients classified under the new system as not having COPD, those patients who were reclassified with a new COPD diagnosis had significantly higher risks for all-cause mortality ...

Related complications are why "COPD is a leading cause of death both in America and worldwide," says Dr. David Mannino, chief medical officer at the COPD Foundation in Florida.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This in-depth analysis shows that the Global Asthma and COPD Drugs Market, valued at ...

Women’s COPD experiences are shaped by different biological, psychological, and social factors compared to men. As such, a care plan that accounts for these differences is more likely to yield ...

Patients with COPD should also be especially careful to avoid exercising outdoors when air quality warnings have been issued, due to their lung sensitivities. Push yourself during exercise, but ...

They identified a total of 20,056 COPD hospitalizations for patients with concurrent HF and 3877 for those without HF. Among patients with HF, 43% had a daily AF burden of at least 6 minutes, and ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is set to grow from sales of $11.5bn in 2023 to $30.8bn in ...

Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

In 2004, Mannino helped to launch the COPD Foundation, where he served as a board member from 2004 through 2015, chairman of the Medical and Scientific Advisory Committee from 2010 through 2015 ...

The Takeaway If you’re living with COPD, it’s critical to reduce your exposure to irritants like smoke, as well as to protect yourself against respiratory infections through vaccinations.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.